Epithelial to Mesenchymal Transition: A Mechanism that Fuels Cancer Radio/Chemoresistance
Open accessThe DOI matches its Crossref record; 136 of the 137 references it cites were found in a registry or an index.
Abstract
Epithelial to mesenchymal transition (EMT) contributes to tumor progression, cancer cell invasion, and therapy resistance. EMT is regulated by transcription factors such as the protein products of the SNAI gene family, which inhibits the expression of epithelial genes. Several signaling pathways, such as TGF-beta1, IL-6, Akt, and Erk1/2, trigger EMT responses. Besides regulatory transcription factors, RNA molecules without protein translation, micro RNAs, and long non-coding RNAs also assist in the initialization of the EMT gene cluster. A challenging novel aspect of EMT research is the investigation of the interplay between tumor microenvironments and EMT. Several microenvironmental factors, including fibroblasts and myofibroblasts, as well as inflammatory, immune, and endothelial cells, induce EMT in tumor cells. EMT tumor cells change their adverse microenvironment into a tumor friendly neighborhood, loaded with stromal regulatory T cells, exhausted CD8+ T cells, and M2 (protumor) macrophages. Several EMT inhibitory mechanisms are instrumental in reversing EMT or targeting EMT cells. Currently, these mechanisms are also significant for clinical use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Main EMT regulatory mechanisms. EMT is a product of internal and external events in cells. It is mainly induced by external factors, such as TGF-β1, neurotrophins, or interleukin-6, which activate several signaling pathways such as WNT, Smads, STATs, Akt, or Erk1/2. The activated pathways drive transcription factors (Goosecoid, Snail, Slug, Twist, nuclear factor erythroid-2-related factor 2 (NRF2), and Krüppel-like factors (KLFs)) to bind to special responding sequences in DNA, and, consequently, these mainly suppress the expression of genes related to epithelial differentiation. The best-known event in this process is the down-regulation of E-cadherin by the SNAI transcription factors, Snail, and Slug. At the same time, mesenchymal gene products, such as vimentin, are induced during the transcriptional changes in the EMT process, where the Smad, HIF-1α, and KLF4 transcription factors are directly involved [43,44]. The transcription regulatory process during EMT does not only rely on transcription factors, but also on long noncoding RNAs (lncRNAs) and microRNAs. The external EMT-inducing factors, such as TGF-β1, neurotrophins, or interleukin-6, are available from the fibroblastic and inflammatory microenvironment, but tumor cells also actively participate in the completion of an EMT program [45]. Based on the experimental data of several research groups, including ours, it has been found that acidic extracellular conditions and, in a further step, a low oxygen tension (hypoxia) are necessary for EMT. Interestingly, EMT tumor cells produce immune checkpoint regulatory molecules and actively remodel their immune microenvironment into a more tumor-friendly one from a hostile neighborhood.](https://figures.cochat.ai/paper-figures/d094b8bd283a4ef386664d3b8450b072/epithelial-to-mesenchymal-transition-a-mechanism-that-fuels-cancer-radio-figure-1.jpg)
![Figure 2 The TGF-β1 gradient causes heterogeneity in the tumor cell nests. There are higher TGF-β1 concentrations near the tumor vasculature, and the tumor cell nest has a decreasing gradient from its border towards the middle, which generates heterogeneity between the tumor–stroma interface and the tumor cell nest center [47]. The TGF-β1 gradient contributes to the heterogenic architecture of the tumor cell nest, where the invasive front has a completely different functional and differentiation profile than the core of the tumor cell nest. Additionally, at the invasive front, tumor cells interact with fibroblasts, leukocytes, and other stromal cells. Some scattered tumor cells undergo EMT at the tumor cell nest–stroma interface and contain both epithelial and mesenchymal markers. The figure is based on a figure published by Mayorca-Giuliani and Erler [48], which has been updated by the published data of Nieto et al. [29].](https://figures.cochat.ai/paper-figures/38bb690ce5c7436d87781e26d39438ba/epithelial-to-mesenchymal-transition-a-mechanism-that-fuels-cancer-radio-figure-2.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These include altered drug transport, e.g., overexpression of drug efflux pumps like ABC transporters, activation of cell survival signaling pathways such as PI3K/AKT, and deregulation of apoptotic pathways leading to resistance to apoptosis [76].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [76]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“Tumor-associated chronic inflammation is a hallmark of cancer [72], which fosters the progression to metastasis [37].”
BackgroundNieto, M. A., Huang, R. Y.-J., Jackson, R. A., & Thiery, J. P. (2016) · Cell · doi:10.1016/j.cell.2016.06.028 · Cited by 4,492
Gregory, P. A., Bert, A. G., Paterson, E. L., Barry, S. C., Tsykin, A., Farshid, G., Vadas, M. A., Khew-Goodall, Y., & Goodall, G. J. (2008) · Nature Cell Biology · doi:10.1038/ncb1722 · Cited by 3,863
Cano, A., Pérez-Moreno, M. A., Rodrigo, I., Locascio, A., Blanco, M. J., del Barrio, M. G., Portillo, F., & Nieto, M. A. (2000) · Nature Cell Biology · doi:10.1038/35000025 · Cited by 3,668
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Epithelial-Mesenchymal Transition: At the Crossroads of Development and Tumor Metastasis
Yang, J., & Weinberg, R. A. (2008) · Developmental Cell · doi:10.1016/j.devcel.2008.05.009 · Cited by 3,012 · cited 1×
“The E-cadherin promoter is hypermethylated in leukemia, which leads to the loss of this protein [56], as in the tumor cells of solid tumors, which can lose E-cadherin by down-regulating EMT [24].”
BackgroundEMT, CSCs, and drug resistance: the mechanistic link and clinical implications
Shibue, T., & Weinberg, R. A. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.44 · Cited by 2,539 · cited 1×
“Nevertheless, the EMT-TFs play even more important pleiotropic roles [4] in invasive, disseminating, and progressive cancer.”
BackgroundZheng, X., Carstens, J. L., Kim, J., Scheible, M., Kaye, J., Sugimoto, H., Wu, C.-C., LeBleu, V. S., & Kalluri, R. (2015) · Nature · doi:10.1038/nature16064 · Cited by 2,032 · cited 4×
“One option to obtain better proof is the identification of EMT cells in tumor tissue sections by selective, reliable, and sensitive immunolabelling [30].”
BackgroundInfluentialBrabletz, T., Kalluri, R., Nieto, M. A., & Weinberg, R. A. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.118 · Cited by 1,961 · cited 9×
“Importantly, both directions of trans-differentiation are reactivated in many cancer types, but a full transition from an epithelial starting point into a differentiated fibroblastic endpoint with the expression of a fibroblast surface protein or vimentin is rarely executed [2,3].”
BackgroundInfluentialStructure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
Aller, S. G., Yu, J., Ward, A., Weng, Y., Chittaboina, S., Zhuo, R., Harrell, P. M., Trinh, Y. T., Zhang, Q., Urbatsch, I. L., et al. (2009) · Science · doi:10.1126/science.1168750 · Cited by 1,929 · cited 1×
“EMT cells overexpress the ABC transporters [97,98].”
Cited by
Items 101–200 of 211
Li, X., Escoffier, H., Sauter, T., & Tavassoli, M. (2025) · Cancers · doi:10.3390/cancers17020267 · Cited by 16
“21 of 30 Cancers 2025 , 17 , x FOR PEER REVIEW 21 of 30 characteristics of RR cells and their maintained radioresistance are linked through a common IL-6 pathway, scratch assays and spheroid assays were performed on RR cells.”
Head and neck cancer – emerging targeted therapies
Abouelkheer, Y., & Bhatia, A. K. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1640960 · Cited by 12
Expression, Localization and Prognosis Association of MEP50 in Breast Cancer
Suresh, S., Vinet, M., Dakroub, R., Lesage, L., Ye, M., Fayyad‐Kazan, H., Nicolas, A., Meseure, D., & Dubois, T. (2022) · Cancers · doi:10.3390/cancers14194766 · Cited by 10
Ghionescu, A.-V., Sorop, A., Linioudaki, E., Coman, C., Savu, L., Fogarasi, M., Lixandru, D., & Dima, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-77416-4 · Cited by 8
In Vitro Magnetic Techniques for Investigating Cancer Progression
Libring, S., Enríquez, Á., Lee, H., & Solorio, L. (2021) · Cancers · doi:10.3390/cancers13174440 · Cited by 10
“, spindle-shaped, migratory, loss of cell–cell cluster packing) [13].”
BackgroundWang, J., Yang, C. F., Cao, H., Yang, J., Meng, W., Yu, M., Yu, L., & Wang, B. (2023) · Cell Transplantation · doi:10.1177/09636897231154574 · Cited by 9
Nero, M. D., Colombo, A., Garbujo, S., Baioni, C., Barbieri, L., Innocenti, M., Prosperi, D., Colombo, M., & Fiandra, L. (2023) · Cancers · doi:10.3390/cancers15092498 · Cited by 9
“CAF-induced che oresistance in tu or cells is often associated with tumor progression and metastasis [4].”
BackgroundMasciale, V., Banchelli, F., Grisendi, G., Samarelli, A. V., Raineri, G., Rossi, T., Zanoni, M., Cortesi, M., Bandini, S., Ulivi, P., et al. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107994 · Cited by 12
“According to a study by Katsuno et al. , mesenchymal cells revert to the phenotype of epithelial cells when TGF-b is removed (506 – 508).”
InfluentialPKN2 Is a Dependency of the Mesenchymal-like Cancer Cell State
Killarney, S. T., Mesa, G., Washart, R., Mayro, B., Dillon, K. A., Wardell, S. E., Newlin, M., Lu, M., Rmaileh, A. A., Liu, N., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0928 · Cited by 10
Trejo, J., Koegeboehn, H., Faizuddin, F., Logan, R., Toutoungy, M., Sheikh, A. A., Fandy, T. E., Saucedo, S., Vasquez, V., Nguyen, T., et al. (2026) · Cells · doi:10.3390/cells15020136 · Cited by 11
“M2 TAMs also secrete IL-6 and IL-8, promoting epithelial–mesenchymal transition (EMT) and tumor cell motility [29].”
Wu, L., Yu, Y., Xu, L., Wang, X., Zhou, J., & Wang, Y. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.881875 · Cited by 12
van Santen, V. J. B., Jin, J., Hogervorst, J. M. A., & Bakker, A. D. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.01.066 · Cited by 9
MicroRNAs in Prostate Cancer: Implications for Treatment Response and Therapeutic Targets
Hussein, M. A., & Munirathinam, G. (2023) · Cancers · doi:10.3390/cancers15205023 · Cited by 8
“The role of EMT in chemoresistance is well established in cancer [21].”
BackgroundTripathi, S. K., Sahoo, R. K., & Biswal, B. K. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-02965-4 · Cited by 10
“Various drugs have been known for their potential to inhibit the invasion and migration of tumor cells by targeting differentially expressed EMT markers (Otsuki et al. 2018; Dudás et al. 2020).”
TGF-β induces EMT in thyroid cancer cells by regulating transcription factors
Xiang, J., Lv, N., Yin, S., Zhao, T., Liu, F., Cheng, L., Liu, F., & Kuang, J. (2025) · Thyroid Research · doi:10.1186/s13044-025-00243-w · Cited by 10
“Members of the Snail family of transcriptional repressors (e.g., SNAIL and SLUG) and other repressors of E-cadherin gene expression, such as ZEB1, ZEB2, and TWIST1, have been detected at EMT sites at the leading edge of metastatic tumors [35].”
Morala, J. N., Alonso-Juarranz, M., Barahona, A. F., Terrén, S., Cabezas, S., Falahat, F., Gilaberte, Y., González, S., Juarranz, Á., & Mascaraque, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-57624-8 · Cited by 7
“Nuclear level localization of β-catenin has been related to the expression of genes involved in EMT, invasion, multidrug resistance and stem cell generation in human tumors 33–35 , 51 .”
BackgroundShu, W., Wang, Z., Zhang, W. Y., Zhang, J., Zhao, R., Yu, Z., Dong, K., & Wang, H. (2022) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207325666221005122554 · Cited by 10
Wu, C., Shi, W., & Zhang, S. (2023) · PubMed Central · Cited by 9
Sharma, G., Abdullah, K. M., Qais, F. A., Κhan, P., Cox, J. L., Sarwar, T., Nasser, M. W., Batra, S. K., & Siddiqui, J. A. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.136921 · Cited by 6
Ling, Q., Ong, M., Konukiewitz, B., Braun, R., Marquardt, J. U., Lehnert, H., Kalthoff, H., & Ungefroren, H. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115561 · Cited by 6
Kinesin Facilitates Phenotypic Targeting of Therapeutic Resistance in Advanced Prostate Cancer
Archer, M., Begemann, D. E., Gonzalez‐Kozlova, E., Nepali, P. R., Labanca, E., Shepherd, P. D. A., Dogra, N., Navone, N. M., & Kyprianou, N. (2024) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-23-1047 · Cited by 6
Epithelial–Mesenchymal Transition and Cancer Stem Cells
Tanabe, S. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-12974-2_1 · Cited by 9
The pivotal role of EMT-related noncoding RNAs regulatory axes in hepatocellular carcinoma
Ghionescu, A.-V., Sorop, A., & Dima, S. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1270425 · Cited by 7
Jassi, C., Kuo, W., Chang, Y.-C., Wang, T., Ho, T., Hsieh, D. J., Kuo, C., Chen, M., Li, C., & Huang, C.-Y. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102125 · Cited by 7
“…literature strongly supports the assertion that the transition of cells from an epithelial to a mesenchymal phenotype, a phenomenon known as Epithelial-Mesenchymal Transition (EMT), significantly contributes to the metastasis of cancer cells and the development of resistance to treatment [10,18].”
BackgroundmiR-214-5p increases the radiosensitivity of cervical cancer by targeting ROCK1 expression
Zhang, J., Li, Y., Ren, Y., Li, J., Han, H., & Yan, P. (2023) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/166673 · Cited by 6
Ingruber, J., Greier, M. D. C., Ladányi, A., & Dudás, J. (2023) · Biomedicines · doi:10.3390/biomedicines11123301 · Cited by 6
“Transforming growth factor beta-1 (TGF-beta-1) acts as an important external factor for the induction of pEMT and the Slug-positive phenotype in HNSCC [7,8,13,16,17].”
BackgroundSelf-citationIngruber, J., Steinbichler, T. B., Vorbach, S. M., Eling, M. T., Borena, W., Seifarth, C., Hofauer, B. G., & Dudás, J. (2025) · Biomedicines · doi:10.3390/biomedicines13020358 · Cited by 6
“The pro-EMT transcription factor (TF) Slug and pEMT were reported to be associated with radiochemotherapy resistance (RCTR) [6,10,11].”
Self-citationBharadwaj, S., Mierzwicka, J. M., Vaňková, L., & Malý, P. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02410-w · Cited by 9
Urbonas, K., Stachnevičiūtė, G., Jasukaitienė, A., Ignatavicius, P., Dambrauskas, Ž., Gulbinas, A., & Barauskas, G. (2026) · PLoS ONE · doi:10.1371/journal.pone.0339964 · Cited by 5
HES1 in cancer: a key player in tumorigenesis and its prognostic significance
Magesh, V., Sekar, R., Alzahrani, A. M., Balasubramanian, R., Abdelsalam, S. A., & Rajendran, P. (2025) · Molecular Genetics and Genomics · doi:10.1007/s00438-025-02259-1 · Cited by 7
“This transition enables cancer cells to detach from the primary tumor, invade surrounding tissues, and ultimately migrate through the bloodstream or lymphatic system, facilitating metastasis to distant organs (Dudas, et al. 2020).”
Kawahara, B., & Mascharak, P. K. (2023) · Medical Research Archives · doi:10.18103/mra.v11i4.3732 · Cited by 6
20 years of taxane therapy in prostate cancer — the past, present and future
Carceles‐Cordon, M., Rodríguez-Bravo, V., Petrylak, D. P., & Domenech, J. M. D. (2025) · Nature Reviews Urology · doi:10.1038/s41585-025-01104-9 · Cited by 5
“A notable limitation of CTCs is the reliance on epithelial epitope-dependent isolation methods, which might fail to detect tumour cells undergoing EMT 273–275 , which can serve as biomarkers of increased metastatic burden, aggressivity and taxane resistance 212,276,277 .”
Zhao, H., Yang, F., Yang, J., & Yang, S. (2025) · Cytokine · doi:10.1016/j.cyto.2025.157090 · Cited by 6
Molecular Mechanisms of Breast Cancer Drug Resistance and CRISPR/Cas9 Strategies to Overcome
Hussen, B. M., Ismael, B. S., Abdulla, S. S., Jamal, N. H., Mustafa, S. A., Najmalddin, Z. B., & Rasul, M. F. (2024) · BioMed Target Journal · doi:10.59786/bmtj.221 · Cited by 5
“Cancer cells may become more mobile as a consequence of the stimulation of EMT-transcription factors (EMT-TFs), enhancing their potential to disseminate and form tumor clusters that can then migrate collectively within a tumor bed 95 .”
NF-κB signaling pathway in osteosarcoma: from signaling networks to targeted therapy
Xue, J.-D., Yang, X., & Wang, L. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1565760 · Cited by 8
Zhou, Y., Liao, L., Su, N. Y., Huang, H., Yang, Y., Yang, Y. F., Wang, G., Xu, H., & Jiang, H. (2022) · Radiation Medicine and Protection · doi:10.1016/j.radmp.2022.05.003 · Cited by 4
Wilczak, M., Surman, M., & Przybyło, M. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128326325240723051625 · Cited by 5
van Santen, V. J. B., Zandieh‐Doulabi, B., Semeins, C. M., Hogervorst, J. M. A., Bratengeier, C., & Bakker, A. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24010759 · Cited by 4
Human Oral Mucosa as a Potentially Effective Source of Neural Crest Stem Cells for Clinical Practice
Bardag‐Gorce, F., Dahan, M. A., Narwani, K., Terrazas, J., Ferrini, M. G., Calhoun, C. C., Uyanne, J., Royce-Flores, J., Crum, E., & Niihara, Y. (2023) · Cells · doi:10.3390/cells12182216 · Cited by 4
“SNAI1 gene expression is known to be responsible for inducing the epithelial-to-mesenchymal transition (EMT) and the loss of epithelial markers [27].”
BackgroundReason, E. H., Thomas, S. M., Chanenchuk, T., van den Bruele, A. B., DiNome, M. L., Hwang, E. S., Parrish, K. J. M., Wang, T., Plichta, J. K., Thomas, A., et al. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-025-17938-x · Cited by 3
“43,44 Ongoing trials continue to explore how molecular features and immunogenics unique to MpBC may be exploited to hopefully improve responses to novel systemic therapies.”
Steinbauer, S., Cowles, J., Sabbaghi, M., Poppelaars, M., Hussain, A., Wagesreither, M., Laimer-Gruber, D., Tóvári, J., Szakács, G., & Csiszar, A. (2025) · npj Breast Cancer · doi:10.1038/s41523-025-00795-y · Cited by 4
“Epithelial plasticity, including epithelial-to-mesenchymal transition (EMT) contribute to therapy resistance and cancer cell survival after therapy 41 .”
Zhang, Y., Guo, D., Zhou, Y., Wang, C., Su, G., Huang, J., Wan, Y., Zhang, H., Wan, H., Bo, L., et al. (2026) · Biomarker Research · doi:10.1186/s40364-026-00948-6 · Cited by 6
“However, in advanced cancers, tumor cells often become resistant to its cytostatic effects and instead co-opt its signaling to promote tumor progression and immune evasion by inducing EMT, angiogenesis, and the differentiation of Tregs [233–236].”
Jabbari, P., Ardakany, M. R., Ebrahimi, S., & Rezaei, N. (2023) · Epigenomics · doi:10.2217/epi-2023-0078 · Cited by 4
Jing, J., Yan, M., Veeraraghavan, V. P., Mohan, S. K., & Meng, Q. (2022) · Applied Nanoscience · doi:10.1007/s13204-021-02229-0 · Cited by 2
RetractedAlghamdi, S. S., Suliman, R. S., Alshehri, R., Almahmoud, R. S., & Alhujirey, R. I. (2022) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2022.120504 · Cited by 3
Greene, G., Zonfa, I., & Regan, E. R. (2025) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1012735 · Cited by 3
Chen, S., Li, F., Meng, L., Li, Y., Xie, Z., Cui, Y., Han, B., Li, W., Zhou, Z., He, X., et al. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117554 · Cited by 4
Asdemir, A., & Özgür, A. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-02950-x · Cited by 2
“In cancer cells, EMT is involved in tumorigenesis, metastases, the formation of tumor cells with stem cells, and resistance to chemotherapy (Francou and Anderson 2020; Dudas et al. 2020).”
BackgroundZhang, H., Song, J., Ward, R. A., Han, Y., Hunt, A., Shriwas, P., Steed, A., Edwards, C., Cao, Y., Co, M., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1276092 · Cited by 3
Mechanisms of chemotherapy resistance in cervical cancer
Marima, R. M., Mosoane, B., Mtshali, N. Z., Basera, A., Kgatle, M., Grech, G., & Dlamini, Z. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-28985-9.00012-4 · Cited by 2
Fenech, K., Micallef, I., & Baron, B. (2024) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2024.049173 · Cited by 2
“The loss of epithelial gene expression and induction of mesenchymal marker expression causes a shift from an apical-basal polarity to a front-rear polarity, loss of epithelial shape, and the disruption of cell-to-cell junctions, supporting cell migration and invasion [8,9].”
BackgroundImpact of cell plasticity on prostate tumor heterogeneity and therapeutic response
Archer, M., Lin, K. M., Kolanukuduru, K. P., Zhang, J. N., Ben‐David, R., Kotula, L., & Kyprianou, N. (2024) · American Journal of Clinical and Experimental Urology · doi:10.62347/yfrp8901 · Cited by 6
Kumar, P., Khadirnaikar, S., Bhandari, N., Chatterjee, A., & Shukla, S. K. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.885785 · Cited by 2
Amjad, Q., & Shakoori, A. R. (2024) · Pakistan Journal of Zoology · doi:10.17582/journal.pjz/20230125150101 · Cited by 1
“EMT is known as among the basic phenomenon that takes place as soon as the cell decides to invade its neighborhood ( Dudás et al ., 2020 ; Figiel et al ., 2017).”
Rajbongshi, L., Kim, J., Lee, J.-E., Lee, S.-R., Hwang, S.-Y., Kim, Y., Hong, Y. M., Oh, S., Kim, B. S., Lee, D., et al. (2025) · Marine Drugs · doi:10.3390/md23100386 · Cited by 2
“Multiple lines of evidence indicate that epithelial–mesenchymal transition (EMT) is vital for tumor growth, progression, invasion, dissemination, metastasis, and drug resistance [48,49].”
Bhattacharya, S., & Das, R. K. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-11299-0 · Cited by 1
LncRNAs in inflammasome regulation: Orchestrating cancer signaling and chemoresistance
Mukhlif, M. Y., Mahmood, S. H., Khalaf, A. A., Sanghvi, G. V., Ballal, S., Singh, A., Sabarivani, A., Mishra, S. S., Mustafa, Y. F., & Yasin, H. A. (2025) · Seminars in Oncology · doi:10.1016/j.seminoncol.2025.152455 · Cited by 1
Temporal molecular remodeling of T cells informs their possible adaptation in 4T1 tumors
Iftehimul, M., Newman, R. H., Harrison, S. H., Jones, R. B., Muganda, P. M., Holloman, B. L., Hossain, M. T., Rorie, C. J., Thomas, M. D., Graves, J. L., et al. (2025) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2025.12.022 · Cited by 4
Behera, A., Datta, S., Mohanty, S., Mohapatra, P., Ansari, S. A., Podder, S., Rath, R. N., Muduly, D. K., Swain, R. K., Raghav, S. K., et al. (2026) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.111126 · Cited by 3
“The EMT not only contributes to changes in morphology and motility of cancer cells to augment invasion, but it also contributes to other aspects of tumorigenesis, like drug resistance (13).”
Razavi, Z.-S., Mottaghi, A., Dmitrieva, L., Fallahianshafiei, S., Olfat, E., & Ahmadi, N. (2026) · Annals of Biomedical Engineering · doi:10.1007/s10439-025-03963-0 · Cited by 2
“Recurrence and therapeutic failure are caused by a number of mechanisms, including tumor-induced immunosuppression, epithelial-to-mesenchymal transition (EMT), ATP-binding cassette (ABC) transporters, and drug efflux [2].”
Chen, X., Ma, X., Yuan, L., Wang, F., Zhang, Y., Fang, J., Cao, P., Wang, T., Xiong, M., Yang, J., et al. (2026) · British Journal of Cancer · doi:10.1038/s41416-026-03370-9 · Cited by 2
Pantelaiou‐Prokaki, G., Bamahmoud, H., Georges, N. S., Jansari, S., Jung, A., Grimm, D. G., Prokakis, E., Gayer, F. A., Deldar, M., Dullin, C., et al. (2026) · International Journal of Cancer · doi:10.1002/ijc.70487 · Cited by 1
“A closer examination of the gene coding for transcription factors (TFs) known to promote the epithelial phenotype and associated with E/m states [24], such as Ovol1 , Grhl2 , Sox9 , and Cebpd , revealed consistent upregulation following treatment with higher radiation doses in mH8N8 cells (Figure…”
InfluentialShukla, S., Sharma, M. P., Rashmi, R., & Misra, G. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-11886-9 · Cited by 1
“Growing evidence also links lncRNAs to therapy resistance through modulation in drug metabolism, efflux, and DNA repair mechanisms [ 15].”
Jiang, Z., Ni, J., Zhou, S., Liu, Y., Huang, X., Bao, J., & Liu, J. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105584 · Cited by 1
Torres, M. J., Ríos, J. C., Valle, A., Indo, S., Gv, K. B., López‐Moncada, F., Faúndez, M., Castellón, E. A., & Contreras, H. R. (2024) · Current Therapeutic Research · doi:10.1016/j.curtheres.2024.100765 · Cited by 1
Suppression of PP2A-B56α drives EMT in EGFR mutant non-small cell lung cancer
Heil, B. N., Baral, G., Pfeffer, C. M., Bahler, M. B., Gulavani, S. S., Smith, E. G., Gartenhaus, L. E., Darling, A. K., Clifford, S. J., Smith-Kinnaman, W. R., et al. (2026) · Oncogene · doi:10.1038/s41388-026-03772-2 · Cited by 1
“Cancer cells can undergo EMT in response to a wide variety of signals, including therapeutic stress, without the need for additional oncogenic mutations, suggesting that posttranslational signaling mechanisms play a key role in driving EMT [4, 5].”
ITGA3 Is a Reliable Biomarker and Putative Therapeutic Target for GliomaPreprint
Zhang, Q. H., Zhu, C., Guan, G., Shen, S., Han, Y., Yang, L.-H., Cheng, W., & Wu, A. (2020) · Research Square · doi:10.21203/rs.3.rs-131679/v1 · Cited by 1
Effect of eribulin on angiogenesis and endothelial adhesion moleculesPreprint
Abbona, A., Falletta, A., Paccagnella, M., Astigiano, S., Martini, S., Denaro, N., Ruatta, F., Barbieri, O., Merlano, M. C., & Garrone, O. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.28.466220 · Cited by 1
MacFawn, I. (2020) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.7778
Wu, H., Wang, W., & Zhu, J. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02609-6
A Review on Systemic and New Cancer Hallmarks
Ingole, A. A., Petle, A. V., Dhoke, S. B., Balgote, P. J., Mukherjee, A. G., & Wanjari, U. R. (2021) · Acta Scientific Cancer Biology · doi:10.31080/ascb.2021.04.0336
Oh, C. R., Kim, H., Ryu, Y., Lee, S., Kim, D., Lee, D. S., Jeong, J. H., Chang, H.-M., Ryoo, B., Kim, K., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-948152/v1
Effect of Eribulin on Angiogenesis and Endothelial Adhesion Molecule Expression.Preprint
Abbona, A., Paccagnella, M., Astigiano, S., Martini, S., Denaro, N., Ruatta, F., Barbieri, O., Merlano, M. C., & Garrone, O. (2021) · Research Square · doi:10.21203/rs.3.rs-1066959/v1
Marinova, L., Yordanova, B. G., & Evgeniev, N. (2021) · Clinical Oncology Research and Reports · doi:10.31579/2693-4787/027
Marinova, L., Evgeniev, N., & Solakova, G. (2021) · Journal of Medical - Clinical Research & Reviews · doi:10.33425/2639-944x.1206
“Surgically treated advanced stage TCCs do not have a significantly better prognosis after platinum/taxane-based chemotherapy compared with serous endometrial ovarian carcinomas [37].”
BackgroundInfluentialLi, R., Zeng, R., Wang, H., Qiu, Y., & Zhang, L. (2022) · Research Square · doi:10.21203/rs.3.rs-1217308/v1
Oh, C. R., Kim, H., Ryu, Y., Lee, S., Kim, D., Lee, D. S., Jeong, J. H., Chang, H.-M., Ryoo, B., Kim, K., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-948152/v2
Traberg, W. C., Uribe, J., Druet, V., Hama, A., Moysidou, C., Huerta, M., McCoy, R. S. A., Hayward, D., Savva, A., Genovese, A. M. R., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1697648/v1
Nersisyan, S. A. (2022) · Вестник Российского государственного медицинского университета · doi:10.24075/vrgmu.2022.028
Isoforms of miR-148a and miR-203a are putative suppressors of colorectal cancer
Nersisyan, S. A. (2022) · Bulletin of Russian State Medical University · doi:10.24075/brsmu.2022.028
LPAR5 confers cancer cells radioresistance associated with EMT activation via ERK/ Snail pathwayPreprint
Sun, X., li, H., Xie, D.-F., Gao, S., Huang, X., Guan, H., Bai, C., & Zhou, P. (2022) · Research Square · doi:10.21203/rs.3.rs-1742763/v1
Deciphering the gene regulatory circuitry governing chemoresistance in Triple-Negative Breast CancerPreprint
Lusby, R., Zhang, Z., Mahesh, A., & Tiwari, V. K. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.05.539623
“1D), processes associated with EMT, confirming the results from Kim et al, and which have previously been implicated in TNBC chemoresistance 24 .”
ResultNovel In Vitro Models for Healthy and Pathological Tissue Formation in Bone and Muscle
van Santen, V. J. B. (2023) · doi:10.5463/thesis.273
Inflammatory Chemokines as Potential Reversal Agents for Tamoxifen Resistance in Breast Cancer CellsPreprint
Ashfaq, I., Munir, A., Izza, B. E. J., Shaukat, H., Pervaiz, A., Asghar, M. T., & Tayyeb, A. (2024) · Research Square · doi:10.21203/rs.3.rs-4003035/v1
Elhusseiny, A., Ali, N., & Fakhry, M. (2024) · ERU Research Journal · doi:10.21608/erurj.2024.228118.1067
The PIK3CA Mutation in Advanced Breast Cancer Chemoresistance and Recurrence
Volodimirovich, M. O., Ivanovich, S. I., Oleksandrovich, L. A., Dmitrovich, L. A., Viktorivna, D. I., Viktorivna, D. I., & Mykolaivna, I. O. (2024) · Journal of Angiotherapy · doi:10.25163/angiotherapy.849552
Chen, S., Hu, S., Lin, Y., Liao, W.-L., & Yang, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179572
“The expression of these EMT-TFs is tightly regulated by various signaling pathways, non-coding RNAs, and extracellular mediators [41–43].”
BackgroundSteinbauer, S., Cowles, J., Sabbaghi, M., Poppelaars, M., Hussain, A., Wagesreither, M., Laimer-Gruber, D., Tóvári, J., Szakács, G., & Csiszar, A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.18.633734
Barnekow, E., Liu, W., Andersson, M., von Wachenfeldt, A., Wendt, C., Tham, E., Mints, M., O’Mara, T. A., Hall, P. N., Margolin, S., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125461
Cellular Immune Responses in Tumor Microenvironment
Khamaru, S., Tung, K. S., & Chattopadhyay, S. (2025) · Springer eBooks · doi:10.1007/978-3-031-88695-9_1 · Cited by 1
Transmembrane receptor ROR1 as a therapeutic target in endometrial cancer
Skossyrskiy, V. S., Gilmutdinova, I., Boot, M. S., Zelenchenkova, P. I., Kimutsadze, V. V., Kimutsadze, V. V., Svidinskaya, E. A., Борисович, А. М., & Sosnova, E. A. (2025) · V F Snegirev Archives of Obstetrics and Gynecology · doi:10.17816/aog677746
Molecular Plasticity of T Cells Informs Their Possible Adaptation in 4T1 TumorsPreprint
Iftehimul, M., Newman, R. H., Harrison, S. H., Jones, R. B., Muganda, P. M., Holloman, B. L., Hossain, M. T., Rorie, C. J., Thomas, M. D., Graves, J. L., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.17.683070
Li, H., Bian, C., Zhou, Y., Yu, J., Chen, X., & Zhao, F. (2025) · World Journal of Surgical Oncology · doi:10.1186/s12957-025-04131-3
Sun, X.-Y., li, H., Xie, D., Gao, S.-S., Huang, X., Guan, H., Bai, C.-J., & Zhou, P. (2022) · Figshare · doi:10.6084/m9.figshare.21285833
Sun, X.-Y., li, H., Xie, D., Gao, S.-S., Huang, X., Guan, H., Bai, C.-J., & Zhou, P. (2022) · Figshare · doi:10.6084/m9.figshare.21285827
Sun, X.-Y., li, H., Xie, D., Gao, S.-S., Huang, X., Guan, H., Bai, C.-J., & Zhou, P. (2022) · Figshare · doi:10.6084/m9.figshare.21285842
Ritter, A., Kreis, N.-N., Roth, S., Friemel, A., Safdar, B. K., Hoock, S. C., Wildner, J. M., Allert, R., Louwen, F., Solbach, C., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26564847
Single-Cell Analysis and Cancer Research: Implications for Diagnosis and Treatment
Biswas, P., Rahim, M. A., Chatterjee, D., Ali, M. S., Tabia, J. N., Siam, M. K. S., & Siam, M. K. S. (2026) · Interdisciplinary biotechnological advances · doi:10.1007/978-981-95-3612-2_3
GABPB1 activates transcription of ITPR3 and EMT in OSCC progression
Liu, J., Zhao, C., Yang, S. H., & Li, J. (2026) · Functional & Integrative Genomics · doi:10.1007/s10142-026-01830-2
“Here, we hypothesized that GABPB1 exerts tumor-promoting effects in OSCC by regulating ITPR3 transcription, which in turn affects EMT.”
InfluentialFan, Y., Sahoo, S., Jolly, M. K., & George, J. T. (2026) · BMC Cancer · doi:10.1186/s12885-026-15691-2 · Cited by 1
Metadata
- Authors
- Dudás, J., Ladányi, A., Ingruber, J., Steinbichler, T. B., & Riechelmann, H.
- Affiliations
- Innsbruck Medical University (AT)
- National Institute of Oncology (HU)
- Corresponding author
- Dudás, József
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2020-02-12
- Volume
- 9
- Issue
- 2
- Pages
- 428
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC7072371
- OpenAlex
- W3006507687
- Cited by
- 213
- References
- 137
- Citations by year
- 2026: 21 · 2025: 31 · 2024: 41 · 2023: 34 · 2022: 40 · 2021: 28 · 2020: 16
- FWCI
- 3.17
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Austrian Science Fund (P25869-B13, I3976-B33)
- Nemzeti Kutatási Fejlesztési és Innovációs Hivatal (ANN 128524)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
- Keywords
- epithelial-mesenchymal transition, cancer therapy resistance, radioresistance (biology), chemoresistance, TGF-β1 signaling, microRNA, long non-coding RNA, tumor microenvironment, cancer-associated fibroblasts, myofibroblasts, regulatory T cells, M2 macrophages, CD8+ T cell exhaustion, EMT reversal
- MeSH terms
- Antineoplastic Agents, Phytogenic, Humans, Neoplasms, Transcription Factors, Signal Transduction, Transforming Growth Factor beta, Drug Resistance, Neoplasm, Mitogen-Activated Protein Kinase 3, T-Lymphocytes, Regulatory, Epithelial-Mesenchymal Transition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.